Mechanisms of disease: Helicobacter pylori-related gastric carcinogenesis - Implications for chemoprevention

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 3, Issue 11, 2006, Pages 622-632

  Romano, Marco ^a   Ricci, Vittorio ^b   Zarrilli, Raffaele ^c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CETUXIMAB; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIGALLOCATECHIN; GEFITINIB; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PELITINIB; PROTON PUMP INHIBITOR; RESVERATROL; ROFECOXIB; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN INHIBITOR; VIRULENCE FACTOR;

ANTIOXIDANT ACTIVITY; BACTERIAL VIRULENCE; CANCER MORTALITY; CANCER RISK; CANCER SUSCEPTIBILITY; CELL GROWTH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG MECHANISM; ENVIRONMENTAL FACTOR; EPITHELIUM CELL; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST PATHOGEN INTERACTION; HUMAN; INFLAMMATION; MALIGNANT TRANSFORMATION; MOLECULAR DYNAMICS; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; STOMACH MUCOSA; TISSUE INJURY;

ANTIOXIDANTS; CPG ISLANDS; CYCLOOXYGENASE 2 INHIBITORS; DIETARY SUPPLEMENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33750429604     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0634     Document Type: Review

References (78)

1. Ferlay J et al. (2004) GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No 5, vers 2.0, Lyon: International Agency for Research on Cancer Press
2. Correa P et al. (2004) The future of gastric cancer prevention. Gastric Cancer 7: 9-16
3. Peek RM Jr and Blaser MJ (2002) Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2: 297-301
4. Everhart JE (2000) Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin N Am 29: 559-578
5. Zarrilli R et al. (1999) Molecular response of gastric epithelial cells to Helicobacter pylori-induced cell damage. Cell Microbiol 1: 93-99
6. Parsonnet J et al. (1991) Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325: 1127-1131
7. Forman D et al. (1991) Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. Br Med J 302: 1302-1305
8. Huang JQ et al. (1998) Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114: 1169-1179
9. Uemura N et al. (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784-789
10. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1994) Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 61: 1-241
11. Watanabe T et al. (1998) Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology 111: 642-648
12. Malfertheiner P et al. (2005) Helicobacter pylori eradication has the potential to prevent gastric cancer: A state-of-the-art critique. Am J Gastroenterol 100: 2100-2115
13. Ye W et al. (2004) Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamouscell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 96: 388-396
14. Ernst PB et al. (2006) The translation of Helicobacter pylori basic research to patient care. Gastroenterology 130: 188-206
15. van Doorn LJ et al. (1999). Geographic distribution of vacA types alleles of Helicobacter pylori. Gastroenterology 116: 823-880
16. Peek RM Jr and Crabtree JE (2006) Helicobacter infection and gastric neoplasia. J Pathol 208: 233-248
17. Cooke CL et al. (2005) The role of genome diversity and immune evasion in persistent infection with Helicobacter pylori. FEMS Immunol Med Microbiol 45: 11-23
18. Argent RH et al. (2004) Determinants and consequences of different levels of CagA phosphorylation for clinical isolates of Helicobacter pylori. Gastroenterology 127: 514-523
19. Covacci A et al. (1999) Helicobacter pylori virulence and genetic geography. Science 284: 1328-1333
20. Hatakeyama M (2004) Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 4: 688-694
21. Viala J et al. (2004) Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 5: 1166-1174
22. Covacci A and Rappuoli R (2000) Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. J Exp Med 191: 587-592
23. Amieva MR et al. (2003) Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 300: 1430-1434
24. Bagnoli F et al. (2005) Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells. Proc Natl Acad Sci USA 102: 16339-16344
25. Boquet P et al. (2003) Gastric cell apoptosis and H. pylori: Has the main function of VacA finally been identified? Trends Microbiol 11: 410-413
26. Cover TL and Blanke SR (2005) Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol 3: 320-332
27. Supajatura V et al. (2002) Cutting edge: VacA, a vacuolating cytotoxin of Helicobacter pylori, directly activates mast cells for migration and production of proinflammatory cytokines. J Immunol 168: 2603-2607
28. de Bernard M et al. (2005) The Helicobacter pylori VacA cytotoxin activates RBL-2H3 cells by inducing cytosolic calcium oscillations. Cell Microbiol 7: 191-198
29. Prinz C et al. (2003) Helicobacter pylori virulence factors and the host immune response: Implications for therapeutic vaccination. Trends Microbiol 11: 134-138
30. Aspholm-Hurtig M et al. (2004) Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. Science 305: 519-522
31. Solnick JV et al. (2004) Modification of Helicobacter pylori outer membrane protein expression during experimental infection of rhesus macaques. Proc Natl Acad Sci USA 101: 2106-2111
32. El-Omar EM et al. (2003) Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124: 1193-1201
33. Lu W et al. (2005) Genetic polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor α and risk of gastric cancer in a Chinese population. Carcinogenesis 26: 631-636
34. Ohyauchi M et al. (2005) The polymorphism interleukin 8 2251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut 54: 330-335
35. Figueiredo C et al. (2002) Helicobacter pylori and interleukin 1 genotyping: An opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 94: 1680-1687
36. Kaaks R et al. (1998) Nutrient intake patterns and gastric cancer risk: a case-control study in Belgium. Int J Cancer 78: 415-420
37. Rogers AB et al. (2005) Helicobacter pylori but not high salt induces gastric intraepithelial neoplasia in B6129 mice. Cancer Res 65: 10709-10715
38. Correa P et al. (2000) Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 92: 1881-1888
39. Smith GV and Farthing MJG (2005) The effect of ascorbic acid on Helicobacter pylori induced cyclooxygenase 2 expression and prostaglandin E2 production by gastric epithelial cells in vitro. Helicobacter 10: 83-89
40. Lindholm C et al. (1988) Local cytokine response in Helicobacter pylori-infected subjects. Infect Immun 66: 5964-5971
41. Galgani M et al. (2004) Helicobacter pylori induces apoptosis of human monocytes but not monocytederived dendritic cells: Role of the cag pathogenicity island. Infect Immun 72: 4480-4485
42. Brandt S et al. (2005) NF-kappaB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein. Proc Natl Acad Sci USA 102: 9300-9305
43. Kim S-Y et al. (2006) Helicobacter pylori CagA transfection of gastric epithelial cells induces interleukin-8. Cell Microbiol 8: 97-106
44. Blaser MJ and Atherton JC (2004) Helicobacter pylori persistence: biology and disease. J Clin Invest 113: 321-333
45. Oh JD et al. (2005) Intracellular Helicobacter pylori in gastric epithelial progenitors. Proc Natl Acad Sci USA 102: 5186-5191
46. Gewirtz AT et al. (2004) Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 189: 1914-1920
47. Fu S et al. (1999) Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 116: 1319-1329
48. Busiello I et al. (2004) Helicobacter pylori gamma-glutamyltranspeptidase upregulates COX-2 and EGF-related peptide expression in human gastric cells. Cell Microbiol 6: 255-267
49. Shibayama K et al. (2003) A novel apoptosis-inducing protein from Helicobacter pylori. Mol Microbiol 47: 443-451
50. Houghton J et al. (2005) Gastric cancer originating from bone marrow-derived cells. Science 306: 1568-1571
51. Romano M et al. (1998) Helicobacter pylori up-regulates the expression of epidermal growth factor-related peptides but inhibits their proliferative effect in MKN 28 gastric mucosal cells. J Clin Invest 101: 1604-1613
52. + Helicobacter pylori induce transactivation of the epidermal growth factor receptor in AGS gastric epithelial cells. J Biol Chem 276: 48127-48134
53. Wallasch C et al. (2002) Helicobacter pylori-stimulated EGF receptor transactivation requires metalloprotease cleavage of HB-EGF. Biochem Biophys Res Commun 295: 695-701
54. Romano M et al. (1998) Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biol Chem 273: 28560-28563
55. Caputo R et al. (2003) Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor-, cyclooxygenase-2-dependent mechanism. Clin Cancer Res 9: 2015-2021
56. Tuccillo C et al. (2005) Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. J Pathol 207: 277-284
57. Crawford HC et al. (2003) Helicobacter pylori strain-selective induction of matrix metalloproteinase-7 in vitro and within gastric mucosa. Gastroenterology 125: 1125-1136
58. Wu CY et al. (2005) Helicobacter pylori promote gastric cancer cells invasion through a NF-kappaB and COX-2-mediated pathway. World J Gastroenterol 11: 3197-3203
59. Franco AT et al. (2005) Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc Natl Acad Sci USA 102: 10646-10651
60. Malfertheiner P et al. (2002) Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16: 167-180
61. Wong BC et al. (2004) Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China. JAMA 291: 187-194
62. Hojo M et al. (2002) Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 16: 1923-1932
63. Mera R et al. (2005) Long term follow up of patients treated for Helicobacter pylori infection. Gut 54: 1536-1540
64. Verma M and Srivastava S (2002) Epigenetics in cancer: Implications for early detection and prevention. Lancet Oncol 3: 755-763
65. Parsonnet J et al. (1996) Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials. Lancet 348: 150-154
66. Graham DY and Shiotani A (2005) The time to eradicate gastric cancer is now. Gut 54: 735-738
67. Tseng HH et al. (2003) Compartment theory in Helicobacter pylori-associated gastric carcinogenesis. Anticancer Res 23: 3223-3229
68. Serafini M et al. (2002) Total antioxidant potential of fruit and vegetables and risk of gastric cancer. Gastroenterology 123: 985-991
69. Ristimaki A et al. (1997) Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57: 1276-1280
70. Wang WH et al. (2003) Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: A systematic review and meta-analysis. J Natl Cancer Inst 95: 1784-1791
71. Hu PJ et al. (2004) Chemoprevention of gastric cancer by celecoxib in rats. Gut 53: 195-200
72. Dannenberg AJ et al. (2005) Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol 23: 254-266
73. Grunwald V and Hidalgo M (2003) Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95: 851-867
74. Ciardiello F et al. (2005) Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9: 1546-1556
75. Albini A et al. (2005) Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 65: 10637-10641
76. Beliveau R and Gingras D (2004) Green tea: Prevention and treatment of cancer by nutraceuticals. Lancet 364: 1021-1022
77. Dannenberg AJ and Subbaramaiah K (2003) Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 4: 431-436
78. Playford RJ et al. (2004) Effects of growth factors and receptor blockade on gastrointestinal cancers. Gut 53: 1059-1063